FY2028 Earnings Forecast for LENZ Issued By Leerink Partnrs

LENZ Therapeutics, Inc. (NASDAQ:LENZ) – Research analysts at Leerink Partnrs reduced their FY2028 EPS estimates for shares of LENZ Therapeutics in a research note issued to investors on Wednesday, May 7th. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earnings per share of $1.10 for the year, down from their prior estimate of $1.20. The consensus estimate for LENZ Therapeutics’ current full-year earnings is ($2.18) per share.

LENZ Therapeutics (NASDAQ:LENZ) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.02.

Several other equities research analysts also recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $38.00 price objective on shares of LENZ Therapeutics in a report on Thursday. TD Cowen began coverage on shares of LENZ Therapeutics in a report on Tuesday, March 18th. They set a “buy” rating and a $60.00 price objective for the company. Citigroup raised their target price on shares of LENZ Therapeutics from $44.00 to $47.00 and gave the stock a “buy” rating in a report on Thursday, March 20th. Finally, Piper Sandler started coverage on LENZ Therapeutics in a report on Monday, April 14th. They set an “overweight” rating and a $51.00 price target on the stock. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $46.60.

LENZ Therapeutics Trading Up 1.8 %

LENZ Therapeutics stock opened at $26.34 on Friday. LENZ Therapeutics has a 12 month low of $14.42 and a 12 month high of $38.93. The stock has a fifty day simple moving average of $24.56 and a two-hundred day simple moving average of $27.28. The firm has a market cap of $725.54 million, a price-to-earnings ratio of -5.52 and a beta of 0.41.

Hedge Funds Weigh In On LENZ Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of LENZ Therapeutics during the 4th quarter valued at approximately $29,000. SG Americas Securities LLC increased its stake in shares of LENZ Therapeutics by 20.7% in the fourth quarter. SG Americas Securities LLC now owns 5,458 shares of the company’s stock worth $158,000 after purchasing an additional 935 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of LENZ Therapeutics by 14.5% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,914 shares of the company’s stock valued at $229,000 after purchasing an additional 1,005 shares during the period. Rhumbline Advisers lifted its stake in shares of LENZ Therapeutics by 6.2% during the 4th quarter. Rhumbline Advisers now owns 18,754 shares of the company’s stock valued at $541,000 after buying an additional 1,100 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its holdings in LENZ Therapeutics by 162.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,860 shares of the company’s stock worth $54,000 after buying an additional 1,151 shares during the period. 54.32% of the stock is currently owned by hedge funds and other institutional investors.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.